Target RWE, a leading real-world evidence solutions company, today announced the results of an innovative research study validating the new nomenclature for fatty liver disease in pediatric patients.
Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced ...